SCHEMBL21580680

SCHEMBL21580680

Cc1ccc(Oc2cc(I)ccn2)cc1F

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HAO1 Q9UJM8 2/20 0.38
▸ MAP4K4 O95819 1/20 0.37
▸ MAPK14 Q16539 1/20 0.35
▸ DRD1 P21728 8/20 0.34
▸ PPARG P37231 2/20 0.34
▸ MRGPRX4 Q96LA9 1/20 0.34
▸ KMO O15229 1/20 0.33
▸ NPC1 O15118 1/20 0.32
▸ CASP3 P42574 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ SENP8 Q96LD8 1/20 0.32
▸ SENP7 Q9BQF6 1/20 0.32
▸ SENP6 Q9GZR1 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ SCN9A Q15858 1/20 0.32
▸ LOXL2 Q9Y4K0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21580663 0.86 HAO1 (0.51) HAO1DRD1NPC1RAB9AKDM4E
SCHEMBL21581650 0.84 DRD1 (0.44) HAO1MAP4K4MAPK14DRD1PPARG
SCHEMBL21581646 0.81 PDGFRA (0.40) MAP4K4DRD1KDM4E
SCHEMBL21580706 0.81 PDGFRB (0.40) HAO1DRD1KMO
SCHEMBL21580673 0.79 DRD1 (0.35) HAO1MAPK14DRD1NPC1CASP3
SCHEMBL12907980 0.74 GRM2 (0.43) DRD1PPARGMRGPRX4KMOSCN9A
SCHEMBL21580645 0.74 PDGFRB (0.52) —
SCHEMBL21610256 0.73 MAP4K4 (0.40) HAO1MAP4K4MAPK14DRD1PPARG
SCHEMBL23952709 0.72 KDM4E (0.46) HAO1MAP4K4PPARGNPC1RAB9A
SCHEMBL1697728 0.72 LOXL2 (0.57) HAO1MAP4K4NPC1RAB9ALOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12090146-B2 Substituted-pyridinyl compounds and uses thereof BIONOMICS LIMITED (AU) 2024-09-17 — — US disclosed
EP-3853216-B1 3-[2-(PHENOXY)-4-PYRIDYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DYSFUNCTION AND CNS DISORDERS BIONOMICS LTD (AU) 2024-09-11 — — EP disclosed
EP-3853216-A1 SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF Bionomics Limited (AU) 2021-07-28 — — EP disclosed
WO-2019222816-A1 SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF BIONOMICS LIMITED (AU) 2019-11-28 — — WO disclosed
WO-2019222816-A1 SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF BIONOMICS LIMITED (AU) 2019-11-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12090146-B2 Substituted-pyridinyl compounds and uses thereof GABRE, GAP43, GRIN2A HAO1 4264/4885MAP4K4 1145/4885MAPK14 1980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback